The global Retinal Disease Therapy Options market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.

From a downstream perspective, Diabetic Retinopathy accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Retinal Disease Therapy Options leading manufacturers including Roche, Opthea, Allergan, Kodiak Sciences, Ribomic, REGENXBIO, EyeBio, Horizon Therapeutics, Regeneron Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Roche leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Retinal Disease Therapy Options market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Retinal Disease Therapy Options Market Report

Report Metric	Details
Report Name	Retinal Disease Therapy Options Market
Segment by Type	Oral Medication Therapy Injection Medication Therapy
Segment by Application	Diabetic Retinopathy Retinal Degeneration Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Opthea, Allergan, Kodiak Sciences, Ribomic, REGENXBIO, EyeBio, Horizon Therapeutics, Regeneron Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Retinal Disease Therapy Options study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Retinal Disease Therapy Options Market report?

Ans: The main players in the Retinal Disease Therapy Options Market are Roche, Opthea, Allergan, Kodiak Sciences, Ribomic, REGENXBIO, EyeBio, Horizon Therapeutics, Regeneron Pharmaceutical

What are the Application segmentation covered in the Retinal Disease Therapy Options Market report?

Ans: The Applications covered in the Retinal Disease Therapy Options Market report are Diabetic Retinopathy, Retinal Degeneration, Other

What are the Type segmentation covered in the Retinal Disease Therapy Options Market report?

Ans: The Types covered in the Retinal Disease Therapy Options Market report are Oral Medication Therapy, Injection Medication Therapy

1 Study Coverage

1.1 Introduction to Retinal Disease Therapy Options: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Retinal Disease Therapy Options Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Oral Medication Therapy

1.2.3 Injection Medication Therapy

1.3 Market Segmentation by Application

1.3.1 Global Retinal Disease Therapy Options Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Diabetic Retinopathy

1.3.3 Retinal Degeneration

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Retinal Disease Therapy Options Revenue Estimates and Forecasts 2020-2031

2.2 Global Retinal Disease Therapy Options Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Retinal Disease Therapy Options Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Retinal Disease Therapy Options Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Oral Medication Therapy Market Size by Players

3.3.2 Injection Medication Therapy Market Size by Players

3.4 Global Retinal Disease Therapy Options Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Retinal Disease Therapy Options Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Retinal Disease Therapy Options Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Retinal Disease Therapy Options Market Size by Type (2020-2031)

6.4 North America Retinal Disease Therapy Options Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Retinal Disease Therapy Options Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Retinal Disease Therapy Options Market Size by Type (2020-2031)

7.4 Europe Retinal Disease Therapy Options Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Retinal Disease Therapy Options Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Retinal Disease Therapy Options Market Size by Type (2020-2031)

8.4 Asia-Pacific Retinal Disease Therapy Options Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Retinal Disease Therapy Options Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Retinal Disease Therapy Options Market Size by Type (2020-2031)

9.4 Central and South America Retinal Disease Therapy Options Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Retinal Disease Therapy Options Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Retinal Disease Therapy Options Market Size by Type (2020-2031)

10.4 Middle East and Africa Retinal Disease Therapy Options Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Retinal Disease Therapy Options Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Roche

11.1.1 Roche Corporation Information

11.1.2 Roche Business Overview

11.1.3 Roche Retinal Disease Therapy Options Product Features and Attributes

11.1.4 Roche Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.1.5 Roche Retinal Disease Therapy Options Revenue by Product in 2024

11.1.6 Roche Retinal Disease Therapy Options Revenue by Application in 2024

11.1.7 Roche Retinal Disease Therapy Options Revenue by Geographic Area in 2024

11.1.8 Roche Retinal Disease Therapy Options SWOT Analysis

11.1.9 Roche Recent Developments

11.2 Opthea

11.2.1 Opthea Corporation Information

11.2.2 Opthea Business Overview

11.2.3 Opthea Retinal Disease Therapy Options Product Features and Attributes

11.2.4 Opthea Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.2.5 Opthea Retinal Disease Therapy Options Revenue by Product in 2024

11.2.6 Opthea Retinal Disease Therapy Options Revenue by Application in 2024

11.2.7 Opthea Retinal Disease Therapy Options Revenue by Geographic Area in 2024

11.2.8 Opthea Retinal Disease Therapy Options SWOT Analysis

11.2.9 Opthea Recent Developments

11.3 Allergan

11.3.1 Allergan Corporation Information

11.3.2 Allergan Business Overview

11.3.3 Allergan Retinal Disease Therapy Options Product Features and Attributes

11.3.4 Allergan Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.3.5 Allergan Retinal Disease Therapy Options Revenue by Product in 2024

11.3.6 Allergan Retinal Disease Therapy Options Revenue by Application in 2024

11.3.7 Allergan Retinal Disease Therapy Options Revenue by Geographic Area in 2024

11.3.8 Allergan Retinal Disease Therapy Options SWOT Analysis

11.3.9 Allergan Recent Developments

11.4 Kodiak Sciences

11.4.1 Kodiak Sciences Corporation Information

11.4.2 Kodiak Sciences Business Overview

11.4.3 Kodiak Sciences Retinal Disease Therapy Options Product Features and Attributes

11.4.4 Kodiak Sciences Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.4.5 Kodiak Sciences Retinal Disease Therapy Options Revenue by Product in 2024

11.4.6 Kodiak Sciences Retinal Disease Therapy Options Revenue by Application in 2024

11.4.7 Kodiak Sciences Retinal Disease Therapy Options Revenue by Geographic Area in 2024

11.4.8 Kodiak Sciences Retinal Disease Therapy Options SWOT Analysis

11.4.9 Kodiak Sciences Recent Developments

11.5 Ribomic

11.5.1 Ribomic Corporation Information

11.5.2 Ribomic Business Overview

11.5.3 Ribomic Retinal Disease Therapy Options Product Features and Attributes

11.5.4 Ribomic Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.5.5 Ribomic Retinal Disease Therapy Options Revenue by Product in 2024

11.5.6 Ribomic Retinal Disease Therapy Options Revenue by Application in 2024

11.5.7 Ribomic Retinal Disease Therapy Options Revenue by Geographic Area in 2024

11.5.8 Ribomic Retinal Disease Therapy Options SWOT Analysis

11.5.9 Ribomic Recent Developments

11.6 REGENXBIO

11.6.1 REGENXBIO Corporation Information

11.6.2 REGENXBIO Business Overview

11.6.3 REGENXBIO Retinal Disease Therapy Options Product Features and Attributes

11.6.4 REGENXBIO Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.6.5 REGENXBIO Recent Developments

11.7 EyeBio

11.7.1 EyeBio Corporation Information

11.7.2 EyeBio Business Overview

11.7.3 EyeBio Retinal Disease Therapy Options Product Features and Attributes

11.7.4 EyeBio Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.7.5 EyeBio Recent Developments

11.8 Horizon Therapeutics

11.8.1 Horizon Therapeutics Corporation Information

11.8.2 Horizon Therapeutics Business Overview

11.8.3 Horizon Therapeutics Retinal Disease Therapy Options Product Features and Attributes

11.8.4 Horizon Therapeutics Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.8.5 Horizon Therapeutics Recent Developments

11.9 Regeneron Pharmaceutical

11.9.1 Regeneron Pharmaceutical Corporation Information

11.9.2 Regeneron Pharmaceutical Business Overview

11.9.3 Regeneron Pharmaceutical Retinal Disease Therapy Options Product Features and Attributes

11.9.4 Regeneron Pharmaceutical Retinal Disease Therapy Options Revenue and Gross Margin (2020-2025)

11.9.5 Regeneron Pharmaceutical Recent Developments

12 Retinal Disease Therapy OptionsIndustry Chain Analysis

12.1 Retinal Disease Therapy Options Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Retinal Disease Therapy Options Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Retinal Disease Therapy Options Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Regeneron Pharmaceutical

Opthea

EyeBio

List of Tables

Table 1. Global Retinal Disease Therapy Options Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Retinal Disease Therapy Options Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Retinal Disease Therapy Options Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Retinal Disease Therapy Options Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Retinal Disease Therapy Options Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Retinal Disease Therapy Options Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Retinal Disease Therapy Options by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retinal Disease Therapy Options as of 2024)

Table 11. Global Retinal Disease Therapy Options Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Retinal Disease Therapy Options Companies Headquarters

Table 13. Global Retinal Disease Therapy Options Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Retinal Disease Therapy Options Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Retinal Disease Therapy Options Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Retinal Disease Therapy Options Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Retinal Disease Therapy Options Revenue by Application (2026-2031) & (US$ Million)

Table 21. Retinal Disease Therapy Options High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Retinal Disease Therapy Options Growth Accelerators and Market Barriers

Table 25. North America Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Retinal Disease Therapy Options Growth Accelerators and Market Barriers

Table 27. Europe Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Retinal Disease Therapy Options Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Retinal Disease Therapy Options Investment Opportunities and Key Challenges

Table 31. Central and South America Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Retinal Disease Therapy Options Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Retinal Disease Therapy Options Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Roche Corporation Information

Table 35. Roche Description and Major Businesses

Table 36. Roche Product Features and Attributes

Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Roche Revenue Proportion by Product in 2024

Table 39. Roche Revenue Proportion by Application in 2024

Table 40. Roche Revenue Proportion by Geographic Area in 2024

Table 41. Roche Retinal Disease Therapy Options SWOT Analysis

Table 42. Roche Recent Developments

Table 43. Opthea Corporation Information

Table 44. Opthea Description and Major Businesses

Table 45. Opthea Product Features and Attributes

Table 46. Opthea Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Opthea Revenue Proportion by Product in 2024

Table 48. Opthea Revenue Proportion by Application in 2024

Table 49. Opthea Revenue Proportion by Geographic Area in 2024

Table 50. Opthea Retinal Disease Therapy Options SWOT Analysis

Table 51. Opthea Recent Developments

Table 52. Allergan Corporation Information

Table 53. Allergan Description and Major Businesses

Table 54. Allergan Product Features and Attributes

Table 55. Allergan Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Allergan Revenue Proportion by Product in 2024

Table 57. Allergan Revenue Proportion by Application in 2024

Table 58. Allergan Revenue Proportion by Geographic Area in 2024

Table 59. Allergan Retinal Disease Therapy Options SWOT Analysis

Table 60. Allergan Recent Developments

Table 61. Kodiak Sciences Corporation Information

Table 62. Kodiak Sciences Description and Major Businesses

Table 63. Kodiak Sciences Product Features and Attributes

Table 64. Kodiak Sciences Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Kodiak Sciences Revenue Proportion by Product in 2024

Table 66. Kodiak Sciences Revenue Proportion by Application in 2024

Table 67. Kodiak Sciences Revenue Proportion by Geographic Area in 2024

Table 68. Kodiak Sciences Retinal Disease Therapy Options SWOT Analysis

Table 69. Kodiak Sciences Recent Developments

Table 70. Ribomic Corporation Information

Table 71. Ribomic Description and Major Businesses

Table 72. Ribomic Product Features and Attributes

Table 73. Ribomic Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Ribomic Revenue Proportion by Product in 2024

Table 75. Ribomic Revenue Proportion by Application in 2024

Table 76. Ribomic Revenue Proportion by Geographic Area in 2024

Table 77. Ribomic Retinal Disease Therapy Options SWOT Analysis

Table 78. Ribomic Recent Developments

Table 79. REGENXBIO Corporation Information

Table 80. REGENXBIO Description and Major Businesses

Table 81. REGENXBIO Product Features and Attributes

Table 82. REGENXBIO Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. REGENXBIO Recent Developments

Table 84. EyeBio Corporation Information

Table 85. EyeBio Description and Major Businesses

Table 86. EyeBio Product Features and Attributes

Table 87. EyeBio Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. EyeBio Recent Developments

Table 89. Horizon Therapeutics Corporation Information

Table 90. Horizon Therapeutics Description and Major Businesses

Table 91. Horizon Therapeutics Product Features and Attributes

Table 92. Horizon Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Horizon Therapeutics Recent Developments

Table 94. Regeneron Pharmaceutical Corporation Information

Table 95. Regeneron Pharmaceutical Description and Major Businesses

Table 96. Regeneron Pharmaceutical Product Features and Attributes

Table 97. Regeneron Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Regeneron Pharmaceutical Recent Developments

Table 99. Raw Materials Key Suppliers

Table 100. Distributors List

Table 101. Market Trends and Market Evolution

Table 102. Market Drivers and Opportunities

Table 103. Market Challenges, Risks, and Restraints

Table 104. Research Programs/Design for This Report

Table 105. Key Data Information from Secondary Sources

Table 106. Key Data Information from Primary Sources

List of Figures

Figure 1. Retinal Disease Therapy Options Product Picture

Figure 2. Global Retinal Disease Therapy Options Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Oral Medication Therapy Product Picture

Figure 4. Injection Medication Therapy Product Picture

Figure 5. Global Retinal Disease Therapy Options Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Diabetic Retinopathy

Figure 7. Retinal Degeneration

Figure 8. Other

Figure 9. Retinal Disease Therapy Options Report Years Considered

Figure 10. Global Retinal Disease Therapy Options Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 12. Global Retinal Disease Therapy Options Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Retinal Disease Therapy Options Revenue Market Share by Region (2020-2031)

Figure 14. Global Retinal Disease Therapy Options Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Oral Medication Therapy Revenue Market Share by Player in 2024

Figure 17. Injection Medication Therapy Revenue Market Share by Player in 2024

Figure 18. Global Retinal Disease Therapy Options Revenue Market Share by Type (2020-2031)

Figure 19. Global Retinal Disease Therapy Options Revenue Market Share by Application (2020-2031)

Figure 20. North America Retinal Disease Therapy Options Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Retinal Disease Therapy Options Revenue (US$ Million) in 2024

Figure 22. North America Retinal Disease Therapy Options Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Retinal Disease Therapy Options Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Retinal Disease Therapy Options Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Retinal Disease Therapy Options Revenue (US$ Million) in 2024

Figure 29. Europe Retinal Disease Therapy Options Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Retinal Disease Therapy Options Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 32. France Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Retinal Disease Therapy Options Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Retinal Disease Therapy Options Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Retinal Disease Therapy Options Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Retinal Disease Therapy Options Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 44. India Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Retinal Disease Therapy Options Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Retinal Disease Therapy Options Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Retinal Disease Therapy Options Revenue (US$ Million) in 2024

Figure 52. Central and South America Retinal Disease Therapy Options Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Retinal Disease Therapy Options Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Retinal Disease Therapy Options Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Retinal Disease Therapy Options Revenue (US$ Million) in 2024

Figure 58. South America Retinal Disease Therapy Options Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Retinal Disease Therapy Options Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Retinal Disease Therapy Options Revenue (2020-2025) & (US$ Million)

Figure 64. Retinal Disease Therapy Options Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Single-Port Vitrectomy Cutter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13L12609

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Eye Ultrasound Biomicroscope Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32B20021

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Plano-Convex Laser Lenses Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-38C19846

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Heated Eye Masks Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2H20253

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions